Recent findings presented at the American Academy of Orthopaedic Surgeons annual meeting indicate that GLP-1 weight-loss drugs, such as Ozempic and Wegovy, may be linked to increased rates of osteoporosis and gout. This research, led by Dr. John Horneff from the University of Pennsylvania, emerged from clinical observations of patients experiencing tendon tears and prompted a comprehensive analysis of medical records from over 146,000 adults with obesity and Type 2 diabetes. The results revealed a 30% relative increase in osteoporosis risk and a 12% increase in gout among GLP-1 users compared to nonusers.

These findings underscore the need for a nuanced approach to GLP-1 therapy in the context of longevity and healthspan. While these medications offer significant benefits in weight loss and metabolic health, the potential for adverse effects on bone health and connective tissue requires careful consideration. As clinicians increasingly prescribe GLP-1 drugs, integrating strategies such as resistance training and nutritional support will be essential to mitigate risks and promote overall well-being.

For longevity professionals, the key takeaway is the importance of monitoring bone health and muscle integrity in patients undergoing GLP-1 therapy. Emphasizing a holistic approach that includes dietary considerations and physical activity may help preserve healthspan while leveraging the metabolic advantages of these therapies.

Source: longevity.technology